These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 10104391)

  • 21. View from the Nation's Capital.
    Freishtat HW
    J Clin Psychopharmacol; 1985 Apr; 5(2):117-9. PubMed ID: 3988970
    [No Abstract]   [Full Text] [Related]  

  • 22. Vouchers for FDA priority reviews.
    Spatz ID
    Health Aff (Millwood); 2006; 25(4):1184; author reply 1184-5. PubMed ID: 16835203
    [No Abstract]   [Full Text] [Related]  

  • 23. Studies involving orphan products for treating/diagnosing women's diseases.
    Haffner ME
    Food Drug Law J; 1993; 48(2):205-11. PubMed ID: 11653144
    [No Abstract]   [Full Text] [Related]  

  • 24. This Dutchman is flying.
    Watson N
    Fortune; 2003 Jun; 147(13):89-90. PubMed ID: 12827720
    [No Abstract]   [Full Text] [Related]  

  • 25. Rare opportunities appear on the horizon to treat rare diseases.
    Torres C
    Nat Med; 2010 Mar; 16(3):241. PubMed ID: 20208483
    [No Abstract]   [Full Text] [Related]  

  • 26. Should off-label drug use be off-the-table?
    Rivkees SA
    J Pediatr Endocrinol Metab; 2007 Feb; 20(2):171-2. PubMed ID: 17396432
    [No Abstract]   [Full Text] [Related]  

  • 27. EMEA approves OGS drug rejected by FDA.
    Mitchell P
    Nat Biotechnol; 2002 Sep; 20(9):858-9. PubMed ID: 12205490
    [No Abstract]   [Full Text] [Related]  

  • 28. Approval times for supplemental indications for recombinant proteins.
    Gosse ME; Nelson TF
    Nat Biotechnol; 1997 Feb; 15(2):130-4. PubMed ID: 9035135
    [No Abstract]   [Full Text] [Related]  

  • 29. Lucrative niches: how drugs for rare diseases became lifeline for companies.
    Anand G
    Wall St J (East Ed); 2005 Nov; ():A1, A18. PubMed ID: 16502531
    [No Abstract]   [Full Text] [Related]  

  • 30. FDA launches priority vouchers for neglected-disease drugs.
    Waltz E
    Nat Biotechnol; 2008 Dec; 26(12):1315-6. PubMed ID: 19060849
    [No Abstract]   [Full Text] [Related]  

  • 31. Big pharma moves from 'blockbusters' to 'niche busters'.
    Dolgin E
    Nat Med; 2010 Aug; 16(8):837. PubMed ID: 20689537
    [No Abstract]   [Full Text] [Related]  

  • 32. Orphan products: definition and activities.
    Finkel MJ
    Prog Clin Biol Res; 1983; 127():159-71. PubMed ID: 6351098
    [No Abstract]   [Full Text] [Related]  

  • 33. The Minor Use and Minor Species Animal Health Act: past, present, and future.
    Haley CJ
    Food Drug Law J; 2006; 61(1):13-43. PubMed ID: 16838456
    [No Abstract]   [Full Text] [Related]  

  • 34. The design and development of therapeutic agents for neuromuscular diseases.
    Lewis NJ
    Prog Clin Biol Res; 1985; 197():105-10. PubMed ID: 4070284
    [No Abstract]   [Full Text] [Related]  

  • 35. Endovasc establishes orphan drug test.
    Walczak IM
    Diabetes Technol Ther; 2002; 4(5):740-1. PubMed ID: 12458568
    [No Abstract]   [Full Text] [Related]  

  • 36. The fuel to run the orphan drug engine: a medical school-based Orphan Disease Center Program.
    Brewer GJ
    Prog Clin Biol Res; 1985; 197():123-38. PubMed ID: 4070287
    [No Abstract]   [Full Text] [Related]  

  • 37. The Orphan Drug Act. Should it be changed?
    Sanders CA
    Arch Intern Med; 1993 Dec; 153(23):2623-5. PubMed ID: 8250658
    [No Abstract]   [Full Text] [Related]  

  • 38. Orphan Drug Act. Winners to keep all.
    Gershon D
    Nature; 1990 Jun; 345(6278):759. PubMed ID: 2359451
    [No Abstract]   [Full Text] [Related]  

  • 39. Orphan Drug Act.
    Van Woert MH
    Prog Clin Biol Res; 1985; 197():7-9. PubMed ID: 4070300
    [No Abstract]   [Full Text] [Related]  

  • 40. Perspectives. Orphan Drug Act stumps lawmakers.
    Firshein J
    Faulkner Grays Med Health; 1990 Jun; 44(25):suppl 4 p.. PubMed ID: 10105023
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.